title: Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors.
abstract: Epstein-Barr virus (EBV) infection is associated with a range of human malignancies of lymphocytic and epithelial cell origin. In addition to viral-mediated and genetic oncogenic events that lead to the establishment of EBV-associated malignancies, defects in the immune control of EBV likely play a significant role in promoting the survival of malignant cells. This breakdown in immune surveillance is most evident in immunocompromised transplant patients who are susceptible to the development of post-transplant lymphoproliferative disorders. Observations over the last two decades have shown that reconstitution of EBV-specific cellular immunity via adoptive cell therapy can have a dramatic effect on both preventing and treating post-transplant lymphoproliferative disorders, leading to hope that similar strategies could be effective in preventing more prevalent EBV-associated malignancies.
authors.affiliation: QIMR Berghofer, Tumour Immunology Laboratory, Department of Immunology, 300 Herston Rd, Brisbane 4006, Australia.
authors.forename: Corey
authors.initials: C
authors.lastname: Smith
authors.affiliation: QIMR Berghofer, Tumour Immunology Laboratory, Department of Immunology, 300 Herston Rd, Brisbane 4006, Australia.
authors.forename: Rajiv
authors.initials: R
authors.lastname: Khanna
mesh_terms: D002051:Burkitt Lymphoma / Q000276:immunology / Q000473:pathology / Q000628:therapy; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D016219:Immunotherapy, Adoptive / Q000379:methods*
keywords: EBV; NPC; PTLD; T cells; adoptive immunotherapy